A French study of some 1,050 HIVers found most had “better health-related quality of life” one year into HAART. Two-thirds had an undetectable viral load, and two-thirds had 100-plus CD4 rises—but 11 percent had severe side effects. HIVers who reported worse quality of life one year into HAART were those with mild or no HIV symptoms when they started. Finally, study heads noted that HIVers who said their quality of life had slipped since starting HAART had poorer dose adherence.